Presidential Symposium 2 A Fascinating Era for Myeloproliferative Neoplasms

Chairs: Norio Komatsu (Department of Hematology, Juntendo University Faculty of Medicine, Japan), Yuzuru Kanakura (Sumitomo Hospital)

9:00 AM - 11:10 AM

MRD in AML

Chairs: Shai Izraeli (Division of Pediatric Hematology and Oncology, Schneider Children's Medical Center of Israel, Israel), Toshihiro Miyamoto (Department of Medicine and Biosystemic Science Kyushu University Faculty of Medicine)

2:50 PM - 5:00 PM

Mini-Concert

6:30 PM - 7:00 PM

Platelet CD36 is at the intersection of inflammation and arterial thrombosis

Chair: Kinuko Mitani (Dokkyo Medical University, Department of Hematology and Oncology)

11:20 AM - 12:00 PM

Undecided

Chairs: Takanori Teshima (Department of Hematology, Hokkaido University Faculty of Medicine), Akifumi Takaori-Kondo (Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University)

1:10 PM - 2:40 PM

Educational Lecture 2-2C Preservation of fertility in patients with hematologic malignancies

Chair: Noriko Usui (Div. Clinical Oncol. and Hematology, Dep. Internal Medicine, The Jikei University School of Medicine)

10:30 AM - 11:10 AM

Educational Lecture 2-2E Recent advances in diagnosis and treatment of idiopathic multicentric Castleman disease

Chair: Mitsune Tanimoto (NHO Iwakuni Clinical Center, Japan)

3:35 PM - 4:15 PM

Educational Lecture 2-2D Progress in immune checkpoint inhibitor therapies

Chair: Masaki Yasukawa (Ehime University Proteo-Science Center)

2:50 PM - 3:30 PM

LS2-2 Treatment Strategies for Transplant Ineligible Newly Diagnosed Multiple Myeloma

Chair: Yasushi Takamatsu（Professor of Department of Medical Oncology, Hematology and Infectious Diseases at Fukuoka University Hospital）

Sponsor: Celgene K.K.

12:15 PM - 1:00 PM

MS2-2 Targeted therapy for AML: a focus upon recently-approved agents.

Chair: Hideaki Nakajima（Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine）

Sponsor: DAIICHI SANKYO COMPANY, LIMITED

7:55 AM - 8:40 AM

Educational Lecture 2-2B Cereblon as a primary target of IMiDs

Chair: Naoto Takahashi (Akita Univ. Hematology Nephrology and Rheumatology)

9:45 AM - 10:25 AM

Educational Lecture 2-2A Progress in diagnosis and treatment of autoimmune hemolytic anemia

Chair: Hideho Wada (Department of Hematology, Kawasaki Medical School)

9:00 AM - 9:40 AM

Educational Lecture 2-2F Reconstitution of the hematopoietic system and clinical applications of iPS cells

Chair: Mineo Kurokawa (Department of Hematology and Oncology, The University of Tokyo)

4:20 PM - 5:00 PM

Clinical Debate 2 Malignant Lymphoma 2

Chair: Koji Izutsu (Department of Hematology, National Cancer Center Hospital)

10:10 AM - 11:10 AM

Clinical Debate 1 Malignant Lymphoma 1

Chairs: Koji Kato (Kyushu University Hospital, Department of Hematology, Oncology and Cardiovascular medicine), Kenichi Ishizawa (Department of Third Internal Medicine, Yamagata University Faculty of Medicine)

9:00 AM - 10:00 AM

LS2-3 Multiple Myeloma at the Cutting Edge: What are the CHALLENGES we face today in our clinical practice?

Chair: Kenji Ishitsuka（Department of Hematology and Rheumatology kagoshima University Department of Hematology and Rheumatology kagoshima University Hospital）

Sponsor: Janssen Pharmaceutical K.K.

12:15 PM - 1:00 PM

MS2-3 Therapeutic Strategy 2020 for Multiple Myeloma ~Aiming for deeper responses~

Chair: MASAHIRO ABE（Department of Hematology, Endocrinology and Metabolism, Tokushima University, Japan）

Sponsor: ONO PHARMACEUTICAL CO., LTD.

7:55 AM - 8:40 AM

Clinical Debate 4 Multiple Myeloma 2

Chair: Hirohiko Shibayama (Department of Hematology and Oncology, Osaka University Graduate School of Medicine)

4:00 PM - 5:00 PM

Clinical Debate 3 Multiple Myeloma 1

Chair: Makoto Sasaki (Department of Hematology, Juntendo University)

2:50 PM - 3:50 PM

Educational Lecture 2-4A Monosomy 7: recent progress

Chair: Shinji Nakao (Kanazawa University, Institutes of Medical, Pharmaceutical, and Health Science, Division of Medicine, Hematology)

9:00 AM - 9:40 AM

Educational Lecture 2-4B Role of HDAC isoforms and development of treatment of multiple myeloma using isoform-specific HDAC inhibitors

Chair: Masafumi Taniwaki (Center for Molecular Diagnostics and Therapeutics, Kyoto Prefectural University of Medicine)

9:45 AM - 10:25 AM

Educational Lecture 2-4C Current issues on research regulation and medical data protection in Japan

Chair: Taira Maekawa (Kyoto Prefectural Institute of Public Health and Environment)

10:30 AM - 11:10 AM

Educational Lecture 2-4E Hematopoietic cell transplantation for chronic active EBV infection

Chair: Ayako Arai (Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine)

3:35 PM - 4:15 PM

Educational Lecture 2-4F Management of cytomegalovirus infection after hematopoietic stem cell transplantation

Chair: Yoshinobu Kanda (Division of Hematology, Saitama Medical Center, Jichi Medical University)

4:20 PM - 5:00 PM

Educational Lecture 2-4D Implications of HLA in allogeneic stem cell transplantation

Chair: Masahiro Imamura (Department of Hematology, Sapporo Hokuyu Hospital, Japan)

2:50 PM - 3:30 PM

MS2-4 ALL: challenges and new directions

Chair: Naoto Takahashi（Department of Hematology, Akita University）

Sponsor: Amgen Astellas BioPharma K.K. Medical Affairs

7:55 AM - 8:40 AM

LS2-4 Optimal therapeutic strategies in follicular lymphoma

Chair: Kazuhito Yamamoto（Department of Hematology and Cell Therapy, Aichi Cancer Center）

Sponsors: Chugai Pharmaceutical Co., Ltd.／Nippon Shinyaku Co., Ltd

12:15 PM - 1:00 PM

LS2-5 Current Status and Future of CML treatment

Chair: Koichi Akashi（Department of Medicine and Biosystemic Science, Graduate School of Medical Science, Kyushu University）

Sponsor: Bristol-Myers Squibb K.K.

12:15 PM - 1:00 PM

MS2-5 High resolution imaging unveils molecular mechanisms of T cell activation to contribute developing cancer immune therapies - Signalosomes constructed by immune-check point and chimeric antigen receptors-

Chair: Masaki Yasukawa（Ehime University, Proteo-Science Center）

Sponsor: MSD K.K.

7:55 AM - 8:40 AM

Epidemiology, Diagnosis and Treatment of Myeloproliferative Neoplasms in Asian Countries

Chairs: Yuzuru Shimoda ( Division of Gastroenterology and Hematology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki), Dong-Tsamn Lin (Laboratory medicine and Pediatrics, National Taiwan University Hospital, Taipei, Taiwan)

2:50 PM - 5:00 PM

Symposium 6 Aiming for Safer Transplants

Chairs: Yoshihiro Inamoto (Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital), Ken-ichi Matsuoka (Department of Hematology and Oncology, Okayama University Graduate School of Medicine)

9:00 AM - 11:10 AM

Educational Lecture 2-6D Lymphomagenesis and epigenetics

Chair: Kensei Tobinai (Department of Hematology, National Cancer Center Hospital)

2:50 PM - 3:30 PM

LS2-6 Treatment strategy for Diffuse large B-cell lymphoma

Chair: Hirokazu Nagai（National Hospital Organization Nagoya Medical Center）

Sponsor: Kyowa Kirin Co., Ltd.

12:15 PM - 1:00 PM

Educational Lecture 2-6A Metabolic reprogramming of leukemia cell fate

Chair: Toshio Suda (International Research Center for Medical Sciences, Kumamoto University, Japan)

9:00 AM - 9:40 AM

Educational Lecture 2-6B Significance and purification of long-term hematopoietic stem cells in the hematopoietic system

Chair: Hideaki Nakajima (Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine)

9:45 AM - 10:25 AM

Educational Lecture 2-6E Exploring the mysteries of megakaryocytopoiesis and thrombopoiesis through comparative hematology

Chair: Kenichi Sawada (Utsukusigaoka Hospital)

3:35 PM - 4:15 PM

Educational Lecture 2-6F Exosomes in the hematopoietic system

Chair: Kazuma Ohyashiki (Department of Hematology, Tokyo Medical University, Tokyo, Japan)

4:20 PM - 5:00 PM

MS2-6 Current Trends and Issues in the Treatment of Non-Hodgkin Lymphomas

Chair: Kiyoshi Ando（Department of Hematology and Oncology, Tokai University School of Medicine）

Sponsor: Celgene K.K.

7:55 AM - 8:40 AM

Educational Lecture 2-6C Cellular senescence and age-related diseases

Chair: Atsushi Hirao (Division of Molecular Genetics, Kanazawa University, Cancer Research Institute)

10:30 AM - 11:10 AM

Oral Session 2-7D Indolent Lymphoma: Novel Therapy

Chair: Wataru Munakata (Department of Hematology, National Cancer Center Hospital)

4:00 PM - 5:00 PM

LS2-7 How We Treat ITP in New Era? ~ Key Points of the Revised Reference Guide

Chair: Takayuki Ikezoe（Department of Hematology, Fukushima Medical University）

Sponsor: Novartis Pharma K.K.

12:15 PM - 1:00 PM

MS2-7 The new era of hemophilia treatment

Chair: Michio Sakai（Pediatrics, MUNAKATA SUIKOKAI GENERAL HOSPITAL）

Sponsor: CHUGAI PHARMACEUTICAL CO., LTD.

7:55 AM - 8:40 AM

Oral Session 2-7C ATL: Treatment

Chair: Masao Matsuoka (Dept Hematol, Rheumatol, and Inf Dis, Kumamoto University)

2:50 PM - 3:50 PM

Oral Session 2-7A Aggressive Lymphoma: Clinical (1)

Chair: Rika Sakai (Kanagawa Cancer Center Department of Medical Oncology)

9:00 AM - 10:00 AM

Oral Session 2-7B Aggressive Lymphoma: Clinical (2)

Chair: Kazuyuki Shimada (Department of Hematology, Nagoya University Hospital)

10:10 AM - 11:10 AM

LS2-8 Opening new era of PNH（paroxysmal nocturnal hemoglobinuria） - Encounter with the first and only long-acting C5 inhibitor ‘Ultomiris^®’ and ‘Attention!’-

Chair: Kinuko Mitani（Department of Hematology and Oncology, Dokkyo Medical University School of Medicine）

Sponsor: Alexion Pharma GK

12:15 PM - 1:00 PM

Oral Session 2-8A Viral Infection

Chair: Hiromichi Iwasaki (Dep of Infect Control Prevent, University of Fukui)

9:00 AM - 10:10 AM

Oral Session 2-8D Coagulation

Chair: Yuko Suzuki (Department of Medical Physiology, Hamamatsu University School of Medicine)

4:00 PM - 5:00 PM

Oral Session 2-8C Hemophilia

Chair: Teruhisa Fujii (Division of Blood Transfusion, Hiroshima University Hospital)

2:50 PM - 3:50 PM

MS2-8 Epigenetic basis of B-cell lymphomas

Chair: Akifumi Takaori-Kondo（Department of Hematology/Oncology Graduate School of Medicine, Kyoto University）

Sponsor: Eisai Co., Ltd. Medical HQs

7:55 AM - 8:40 AM

Oral Session 2-8B Viral Infection: CMV

Chair: Shingo Yano (The Jikei University School of Medcine Division of Clinical Oncology and Hematology)

10:10 AM - 11:10 AM

MS2-9 Risk management of Tumor lysis syndrome

Chair: Kenichi Ishizawa（Department of Third Internal Medicine Division of Hematology and Cell Therapy, Yamagata University Faculty of Medicine）

Sponsor: Sanofi K.K.

7:55 AM - 8:40 AM

Oral Session 2-9C Multiple Myeloma: Basic (Novel Molecular Targets）

Chair: Yutaka Hattori (Div. of Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University)

2:50 PM - 3:50 PM

Oral Session 2-9A Multiple Myeloma: Basic (1)

Chair: Naoki Hosen (Dept of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine)

9:00 AM - 10:00 AM

LS2-9 Mutational landscape in MPN: towards personalized therapy

Chair: Yuzuru Kanakura（Sumitomo Hospital）

Sponsor: PharmaEssentia Japan KK

12:15 PM - 1:00 PM

Oral Session 2-9D Multiple Myeloma: Clinical (Prognosis/Biomarker/Salvage Therapy)

Chair: Chikako Ohwada (Department of Hematology, Chiba University Hospital)

4:00 PM - 5:00 PM

Oral Session 2-9B Multiple Myeloma: Basic (2)

Chair: Masaki Ri (Division of Blood Transfusion and Cell Therapy, Nagoya City University Hospital)

10:10 AM - 11:10 AM

Oral Session 2-10A Indolent Lymphoma: Treatment

Chair: Ilseung Choi (Dep. Hematology, NHO Kyushu Cancer Center)

9:00 AM - 10:00 AM

LS2-10 Open questions in the management of follicular lymphoma

Chair: Koji Izutsu（Department of Hematology, National Cancer Center Hospital）

Sponsors: Eisai Co., Ltd／SymBio Pharmaceuticals

12:15 PM - 1:00 PM

MS2-10 Hodgkin lymphoma: Current progress and future issues

Chair: Hirohiko Shibayama（Associate Professor, Hematology and Oncology, Division of Medicine, Graduate School of Medicine, Osaka University）

Sponsor: Takeda Pharmaceutical Company Limited

7:55 AM - 8:40 AM

Oral Session 2-10D ATL/HTLV-1: Molecular Mechanism/Therapeutic Target

Chair: Jun-ichirou Yasunaga (Laboratory of Virus Control, Institute for Frontier Life and Medical Sciences, Kyoto University)

4:00 PM - 5:00 PM

Oral Session 2-10C PTCL: Treatment

Chair: Asahi Ito (Depaertment of Hematology and Oncology, Nagoya City University)

2:50 PM - 3:50 PM

Oral Session 2-10B Indolent Lymphoma: Prognostic Factors

Chair: Noriko Fukuhara (Tohoku University Hospital, Department of Hematology and Rheumatology)

10:10 AM - 11:10 AM

Oral Session 2-11C CML: Basic (1)

Chair: Yosuke Minami (Department of Hematology, National Cancer Center Hospital East)

2:50 PM - 3:50 PM

Oral Session 2-11B AML: Clinical Study (2)

Chair: Yukiyasu Ozawa (Japanese Red Cross Nagoya First Hospital)

10:10 AM - 11:10 AM

Oral Session 2-11A AML: Clinical Study (1)

Chair: Takahiro Yamauchi (Department of Hematology and Oncology, Univesity of Fukui)

9:00 AM - 10:00 AM

LS2-11 The WHO classification of MPN – updates in morphology and molecular findings

Chair: Masafumi Ito（Japanese Red Cross Nagoya Daiichi Hospital）

Sponsor: Takeda Pharmaceutical Company Limited

12:15 PM - 1:00 PM

Oral Session 2-11D CML: Basic (2)

Chair: Tomoiku Takaku (Department of hematology Juntendo university School of Medicine)

4:00 PM - 5:00 PM

MS2-11 Past, present and future of acute promyelocytic leukemia

Chair: Norio Asou（Department of Hematology International Medical Center Saitama Medical University）

Sponsor: Fuji Pharma Co., Ltd.

7:55 AM - 8:40 AM

Oral Session 2-12C ALL: Clinical (3)

Chair: Motohiro Kato (National Center for Child Health and Development)

2:50 PM - 3:50 PM

Oral Session 2-12D Ph+ALL

Chair: Nobuaki Dobashi (Division of Clinical Oncology and Hematology, The Jikei University Daisan Hospital)

4:00 PM - 5:00 PM

MS2-12 Importance of Iron Chelation Therapy in Lower-risk MDS and Scheme to Prevent Overlook

Chairs: Akihiko Gotoh（Department of Hematology, Tokyo Medical University）, Shin Fujisawa（Department of Hematology, Yokohama City University Medical Center）

Sponsor: Novartis Pharma K.K.

7:55 AM - 8:40 AM

Oral Session 2-12A ALL: Clinical (1)

Chair: Kiyotoshi Imai (Department of Hematology, Otaru General Hospital)

9:00 AM - 10:00 AM

Oral Session 2-12B ALL: Clinical (2)

Chair: Etsuko Yamazaki (Clinical Laboratory Department, Yokohama City University Hospital)

10:10 AM - 11:10 AM

LS2-12 Thinking about haemophilia treatment from the factor IX modification technology and their mode of action.

Chair: Midori Shima（Department of Pediatrics Nara Medical University）

Sponsor: Novo Nordisk Pharma Ltd.

12:15 PM - 1:00 PM

Oral Session 2-13C MDS：Basic (2)

Chair: Yuka Harada (Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital)

2:50 PM - 3:50 PM

Oral Session 2-13D MDS：Basic (3)

Chair: Masashi Sanada (Clinical Research Center, National Hospital Organization Nagoya Medical Center)

4:00 PM - 5:00 PM

MS2-13 Autoimmune hemolytic anemia (AIHA) –Revision of Guideline and Risk of Thromboembolism-

Chair: Hideo Harigae（Hematology and Rheumatology, Tohoku University, Graduate School of Medicine）

Sponsor: Sanofi K.K.

7:55 AM - 8:40 AM

Oral Session 2-13A MDS：Basic (1)

Chair: Hirotaka Matsui (Department of Molecular Laboratory Medicine, Kumamoto University)

9:00 AM - 10:00 AM

Oral Session 2-13B MDS：Clinical (1)

Chair: Akira Matsuda (Department of Hemato-Oncology, International Medical Center, Saitama Medical University)

10:10 AM - 11:10 AM

LS2-13 Modeling Plasma Cell Microenvironment Interactions to Improve Clinical Decision Making in Multiple Myeloma.

Chair: Kazuyuki Shimizu（Higashinagoya National Hospital）

Sponsor: Fujimoto Pharmaceutical Corporation

12:15 PM - 1:00 PM

Oral Session 2-14A CAR T Therapy

Chair: Ken Ohmine (Division of Hematology, Department of Medicine, Jichi Medical University)

9:00 AM - 10:00 AM

Oral Session 2-14D Post-transplant Complications/Graft Failure/Endothelial Injury

Chair: Toshiro Kurokawa (Toyama Red Cross Hospital, Division of Hematology)

4:00 PM - 5:00 PM

Oral Session 2-14C Post-transplant: Prognosis

Chair: Kazuhiro Ikegame (Hyogo College of Medicine, Division of Hematology, Department of Medicine)

2:50 PM - 3:50 PM

Oral Session 2-14B Gene-modified T Cell Therapy

Chair: Yoshiki Akatsuka (Department of Immunology, Graduate School of Medicine, Nagoya University)

10:10 AM - 11:10 AM

MS2-14 How to utilize Factor VIII therapy in Hemophilia A

Chair: Masashi Taki（Department of Pediatrics, St.Marianna University School of Medicine）

Sponsor: Bayer Yakuhin, Ltd.

7:55 AM - 8:40 AM

LS2-14 Novel agents and strategies in PTCL

Chair: Eisei KONDO（Division of Hematology, Department of Medicine, Kawasaki Medical School）

Sponsor: Mundipharma K.K.

12:15 PM - 1:00 PM

Oral Session 2-15D Relapsed Aggressive Lymphoma: Treatment

Chair: Eisei Kondo (Department of Hematology, Kawasaki Medical School, Kurashiki, Japan)

4:00 PM - 5:00 PM

LS2-15 CML －Road to Treatment-free Remission－

Chair: Tetsuya Fukuda（Department of Hematology, Tottori University Hospital）

Sponsor: Otsuka Pharmaceutical Co., Ltd.

12:15 PM - 1:00 PM

MS2-15 Molecular abnormalities in chronic lymphocytic leukemia and mantle cell lymphoma: p53 abnormalities and implications for therapy

Chair: Yasuhito Terui（Director of Hematology Oncology, Cancer Institute Hospital Hematology, JAPANESE FOUNDATION FOR CANCER RESEACH）

Sponsor: Janssen Pharmaceutical K.K., Medical Affairs Division

7:55 AM - 8:40 AM

Oral Session 2-15C Aggressive Lymphoma: CNS/Others

Chair: Takashi Sonoki (Wakayama Medical University Hematology and Oncology)

2:50 PM - 3:50 PM

Oral Session 2-15A Multiple Myeloma: Clinical (2)

Chair: Junya Kuroda (Division of Hematology and Oncology, Kyoto Prefectural University of Medicine)

9:00 AM - 10:00 AM

Oral Session 2-15B Multiple Myeloma: Clinical (3)

Chair: Kazutaka Sunami (National Hospital Organization Okayama Medical Center)

10:10 AM - 11:10 AM

Career Creation for Women Doctors

Chairs: Kinuko Mitani (Dokkyo Medical University, Department of Hematology and Oncology), Masahiro Kizaki (Department of Hematology, Saitama Medical Center, Saitama Medical University, Japan)

9:30 AM - 11:00 AM

LS2-16 Management of secondary hypogammaglobulinemia in hematological malignancies

Chair: Tatsuo Ichinohe（Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University）

Sponsor: CSL Behring K.K.

12:15 PM - 1:00 PM

SETP3 Immunotherapy and Precision Medicine

Commentator: Catherine Wu (Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School)
Moderator: Miki Ando (Juntendo University School of Medicine)

2:50 PM - 3:50 PM

SETP4 Myeloproliferative Neoplasms

Commentator: Ruben Mesa (The UT Health San Antonio MD Anderson Cancer Center, TX, USA)
Moderator: Kazuhiko Ikeda (Department of Blood Transfusion and Transplantation Immunology)

2:50 PM - 3:50 PM

LS2-17 Clinical usefulness of Voriconazole’s TDM for invasive fungal infections

Chair: Satoshi Takahashi（Hematology and Oncology, The University of Tokyo, The Institute of Medical Science）

Sponsor: Pfizer Japan Inc.

12:15 PM - 1:00 PM

Oral Session 2-17A Erythropoiesis: Basic

Chair: Hiroshi Kawabata (Department of Hematology and Immunology, Kanazawa Medical University, Japan)

9:00 AM - 10:00 AM

Oral Session 2-17B Pediatric Hematology

Chair: Mariko Eguchi (Department of Pediatrics, Ehime University Graduate School of Medicine)

10:10 AM - 11:10 AM

Encore of Educational Lecture

9:00 AM - 5:30 PM

Encore of Educational Lecture

9:00 AM - 5:30 PM

Exhibition & Corporate Partner Lounge

9:00 AM - 6:20 PM

Poster Mounting

Sat.Oct,12

8:30 AM - 10:00 AM

Poster Removal

Sat.Oct,12

6:20 PM - 7:00 PM

Poster Discussion

Sat.Oct,12

『ポスター討論の詳細については「ポスター発表タイムテーブル」をご覧ください。』

5:10 PM - 6:20 PM

Reception for all the participants

7:20 PM - 9:00 PM